Bilcare Research

- DMF regd. with USFDA
- EEC / USP
- Member, IQA, London
- OPPI Award Winner
- Pioneer Status from Govt. of Singapore
- ISO 9001:2000 & 14001:2004 Company

Bilcare, an unique organization with a strong research foundation and an unending quest for global leadership. An organization, integrated with global Pharmaceuticals having best in class manufacturing and research facilities spread worldwide. An organization made up of motivated people who go that extra mile to spread excellence and joy.

Bilcare Limited - Regd. Office: 1028, Shiroli, Pune 410 505.

Unaudited Financial Results for the quarter ended 30th June, 2007

(Rs. in Crores)

Sr. No.	Particulars	Quarter Ended 30th June 2007 (Unaudited)	Corresponding Quarter Ended 30th June 2006 (Unaudited)	Previous Year Ended 31st March 2007 (Audited)	Consolidated Quarter Ended 30th June 2007 (Unaudited)	Consolidated Previous Year Ended 31st March 2007 (Audited)
1.	Net Sales / Income from Operations	92.88	72.87	322.98	130.83	407.86
2.	Other Income	0.82	0.32	18.46	1.03	17.87
3.	Total Expenditure a) Increase / Decrease in Stock in Trade b) Consumption of Raw Materials c) Staff Cost d) Other Expenditure	(12.02) 66.65 3.79 8.45	2.79 43.09 1.98 4.91	(1.95) 198.92 12.00 23.98	(13.50) 86.09 13.67 13.56	(5.15) 248.39 22.39 43.11
4.	Interest	2.77	1.46	7.96	3.11	9.12
5.	Depreciation	3.55	2.20	10.72	5.05	15.44
6.	Profit before tax	20.51	16.76	89.81	23.88	92.43
7.	Provision for taxation	6.97	5.64	31.25	7.35	32.51
8.	Net Profit	13.54	11.12	58.56	16.53	59.92
9.	Paid-up Equity Share Capital (face value Rs.10/- each)	15.09	14.20	14.20		
10.	Rerserves excluding Revaluation Reserves			184.33		189.70
11.	EPS for the Period (Rs.)					
	- Basic - Diluted	8.97 8.16	7.83 7.37	41.24 35.29		
12.	Public Shareholding - No. of Shares - Percentage of Shareholding	8512526 56.40%	7754526 54.61%	7619526 53.66%		

Notes:

Pune: July 30, 2007

- 1. The Company's main business segment is advanced pharma packaging solutions.
- 2. The Company had received 3 investor complaints during the quarter, which were redressed and there were no investor complaints pending for redressal at the commencement and at the end of the quarter.
- 3. During the quarter, the Company on May 17, 2007 has allotted 893,000 Equity Shares of Rs.10/- on conversion of Warrant 'B', convertible into Equity Shares of Rs. 10/- each issued at Rs.290/- per share (including premium). Consequently, the Paid-up Equity Share Capital of the Company stands increased to Rs.150,938,000, divided into 15,093,800 Equity Shares of Rs.10/- each.
- 4. During the quarter, Bilcare Singapore Pte. Ltd, a wholly owned subsidiary of Bilcare Ltd. has promoted Bilcare Switzerland SA as its subsidiary Company. Consequently Bilcare Switzerland SA has become subsidiary of the Company.
- 5. The previous year's figures have been regrouped / readjusted wherever necessary.
- 6. The above unaudited Financial Results were taken on record by the Board of Directors of the Company at its meeting held on 30th July, 2007.
- 7. The Company provided for the first time Consolidated quarterly results from the first quarter of the current year and hence figures for the corresponding quarter of the previous year are not available.

For Bilcare Limited

Mohan H. Bhandari

Managing Director

INDIA: USA: SINGAPORE: GERMANY: BRAZIL: CHINA: UK